CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2358
EU - Europa 1930
AS - Asia 1080
OC - Oceania 12
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 7
AF - Africa 2
AN - ???statistics.table.value.continent.AN??? 1
Totale 5399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2342
CN - Cina 1019
GB - Regno Unito 614
FR - Francia 354
IE - Irlanda 312
SE - Svezia 252
UA - Ucraina 121
IT - Italia 98
DE - Germania 79
FI - Finlandia 54
VN - Vietnam 41
BE - Belgio 16
CA - Canada 15
AU - Australia 12
RU - Federazione Russa 8
EU - Europa 7
GR - Grecia 5
NL - Olanda 5
TR - Turchia 5
BR - Brasile 4
CL - Cile 3
JP - Giappone 3
AT - Austria 2
HK - Hong Kong 2
ID - Indonesia 2
IN - India 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
KH - Cambogia 1
KR - Corea 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SG - Singapore 1
Totale 5399
Salva come PNG Salva come JPEG
Città #
Southend 589
Chandler 576
Jacksonville 555
Dublin 307
Lawrence 153
Princeton 153
Wilmington 153
Beijing 148
Jinan 128
Woodbridge 113
Nanjing 111
Shenyang 107
Hebei 67
Tianjin 62
Houston 58
Zhengzhou 46
Ashburn 44
Taizhou 39
Haikou 36
Redmond 36
Ann Arbor 35
Dearborn 35
Jiaxing 34
Grafing 33
Changsha 32
Dong Ket 31
Ningbo 31
Taiyuan 28
Hangzhou 27
Guangzhou 26
Helsinki 25
Nanchang 25
Lanzhou 24
Norwalk 24
Verona 24
Redwood City 22
Fuzhou 17
Brussels 16
San Francisco 13
Boardman 9
Toronto 9
Chicago 7
Fairfield 7
Falls Church 6
Vigasio 6
Canberra 5
Melbourne 5
Berlin 4
Milan 4
Pittsburgh 4
São Paulo 4
Bologna 3
Cambridge 3
Clearwater 3
Fremont 3
Groningen 3
Kemerovo 3
Nardò 3
New York 3
Ortona 3
Padova 3
Rome 3
San Diego 3
Seattle 3
Xiangfen 3
Aberdeen 2
Auburn Hills 2
Catanzaro 2
Düsseldorf 2
Evanston 2
Frankfurt am Main 2
Los Angeles 2
Markham 2
Riva 2
Vienna 2
Abuja 1
Amsterdam 1
Andover 1
Birmingham 1
Boston 1
Budapest 1
Cagliari 1
Central 1
Changle 1
Chaoyang 1
Chisinau 1
Cleveland 1
Dalian 1
Des Moines 1
Dubai 1
Duluth 1
Edmond 1
Garden City 1
Irving 1
Islamabad 1
Kunming 1
Las Vegas 1
Leawood 1
Lima 1
Lisbon 1
Totale 4140
Salva come PNG Salva come JPEG
Nome #
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 102
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 86
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 79
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 76
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 75
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 72
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 71
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 70
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 70
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 69
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 67
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 66
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 61
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 61
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 61
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 61
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 56
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 55
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 55
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 55
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 53
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 53
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 52
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 51
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 51
Computerized drug management in a Bone Marrow Transplant Unit: towards an improvement of hospital drug management 50
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? 50
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 50
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 50
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia 49
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 49
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 49
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 47
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 46
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 46
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 45
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 45
Computer-based drug management in a bone marrow transplant unit:a suitable tool for multiple prescriptions even in critical conditions 44
P53 and p21waf1 expression by immunohistochemistry in diffuse large B-cell lymphoma has a strong and independent impact on survival of patients with germinal center phenotype 44
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 43
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 43
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 43
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 42
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 42
Bendamustine plus rituximab: is it a BRIGHT idea? 42
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 41
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 41
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 40
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 40
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 39
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 39
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma 39
Autoimmune cytopenias in chronic lymphocytic leukemia 39
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 38
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 38
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 37
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 37
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program 37
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 37
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 37
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 37
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 37
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 36
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 36
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL 36
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 36
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 35
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP 34
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 34
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 34
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma 33
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 33
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program 33
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 33
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement 33
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 33
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 33
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 33
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma 32
Immune thrombocytopenia in lymphoproliferative disorders 32
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 32
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 32
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 32
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 32
Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination? 31
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 31
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 31
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 31
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 31
miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy 30
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 30
The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment 30
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 29
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 29
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study 29
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker 29
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 29
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 29
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone 28
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines 28
Totale 4412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13351
article - articoli 12674
book - libri 0
conference - conferenze 677
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201820 0000 00 00 9821
2018/2019307 15193 105 257 13414480
2019/2020874 146191126 47131 33107 308772165
2020/20211258 16522129273 144168 617 232013953
2021/2022920 521941747 3527 4765 353058313
2022/20231923 169173212275 189529 37119 220000
Totale 5579